For atrial fibrillation, oral anti-coagulation remains the treatment of choice despite the potential of an anti-platelet regimen based on aspirin and clopidogrel, according to the ACTIVE-W trial. Stuart Connolly from McMaster University presented the findings.
[audio:https://www.audiomedica.com/podcasting/aha2005/Stuart_Connolly.mp3]
Audio Journal of Cardiovascular Medicine: June 2006 – In the company of Michael Petch 29 May, 2006 Thrombin Receptor Antagonist: Advantages in Percutaneous Coronary Intervention? 25 Mar, 2007 Audio Journal of Cardiovascular Medicine: reporting from American Heart Association Scientific Sessions, Chicago, November 12-15, 2006 16 Nov, 2006 
Direct infusions of HDL to prevent re-infarction in patients with acute coronary syndromes 16 Nov, 2012 
COVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014